# US 2025/0082265 A1 · Treatment of a disease of the gastrointestinal tract with an immunosuppressant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082265 A1
- Document ID: US20250082265A1
- Status: Published application
- Kind: A1
- Application number: 18/959,485
- Filed: 2024-11-25
- Published: 2025-03-13
- Earliest claimed: 2019-06-12
- Assignees: Biora Therapeutics, Inc.
- Applicants: Biora Therapeutics, Inc.
- Inventors: Mitchell Lawrence Jones; Sharat Singh; Christopher Loren Wahl; Harry Stylli
- Web page: https://patentgrep.com/patent/US20250082265A1

## CPC

- A61B 5/4839: {combined with drug delivery}
- A61B 1/041: {Capsule endoscopes for imaging}
- A61B 5/0031: {Implanted circuitry}
- A61B 5/0075: {by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy (A61B5/0071 takes precedence)}
- A61B 5/07: Endoradiosondes
- A61B 5/073: {Intestinal transmitters}
- A61B 5/4887: {Locating particular structures in or on the body}
- A61B 5/6861: {Capsules, e.g. for swallowing or implanting}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61K 38/13: Cyclosporins
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C07K 16/244: {Interleukins [IL]}
- C12M 31/00: {Means for providing, directing, scattering or concentrating light (C12M41/06 takes precedence)}
- C12Q 1/00: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (measuring or testing apparatus with condition measuring or sensing means, e.g. colony counters, C12M1/34); Compositions therefor; Processes of preparing such compositions
- A61B 1/00156: {using self propulsion}
- A61B 5/0071: {by measuring fluorescence emission}
- A61B 2010/0061: {Alimentary tract secretions, e.g. biliary, gastric, intestinal, pancreatic secretions}
- A61B 2562/162: Capsule shaped sensor housings, e.g. for swallowing or implantation
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

## Claims

### Claim 1

A method of treating a disease of the gastrointestinal (GI) tract in a subject, the method comprising orally administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an immunosuppressant and topically delivering the therapeutically effective amount of the immunosuppressant to a desired location in the GI tract of the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the delivery of the therapeutically effective amount of the immunosuppressant at the desired location in the GI tract provides a concentration of the immunosuppressant in the plasma of the subject that is less than 1 μg/ml.

### Claim 3 (depends on 1)

The method of claim 1, wherein the delivery of the therapeutically effective amount of the immunosuppressant at the desired location in the GI tract provides a concentration of the immunosuppressant in the plasma of the subject that is less than 0.3 μg/ml.

### Claim 4 (depends on 1)

The method of claim 1, wherein the delivery of the therapeutically effective amount of the immunosuppressant at the desired location in the GI tract provides a concentration of the immunosuppressant in the plasma of the subject that is less than 0.1 μg/ml.

### Claim 5 (depends on 1)

The method of claim 1, wherein the delivery of the therapeutically effective amount of the immunosuppressant at the desired location in the GI tract provides a concentration of the immunosuppressant in the plasma of the subject that is less than 0.01 μg/ml.

### Claim 6 (depends on 1)

The method of claim 1, wherein the delivery of the therapeutically effective amount of the immunosuppressant results in a decrease of at least one biomarker in the GI tract, wherein the at least one biomarker is selected from the group consisting of interferon-γ, IL-β, IL-6, IL-22, IL-17A, TNFa, IL-2, and combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered in an ingestible device.

### Claim 8 (depends on 1)

The method of claim 1, wherein the therapeutically effective amount of the immunosuppressant is not therapeutic effective if administered systemically.

### Claim 9 (depends on 1)

The method of claim 1, wherein the concentration of the immunosuppressant delivered at the desired location in the gastrointestinal tract is 10%, 25%, 50%, 75%, 100%, 200%, 300%, 400%, 500%, 1000%, 2000% greater than the concentration of immunosuppressant in plasma.

### Claim 10 (depends on 9)

The method of claim 9, wherein the concentration of the immunosuppressant delivered at the desired location in the gastrointestinal tract is measured from a sample comprising GI tissue.

### Claim 11 (depends on 9)

The method of claim 9, wherein the level of immunosuppressant in plasma in a subject at a time point following oral administration of the device is lower than the level of the immunosuppressant in plasma in a subject at substantially the same time point following systemic administration of an equal amount of the immunosuppressant.

### Claim 12 (depends on 1)

The method of claim 1, wherein the desired location is proximate to one or more sites of disease.

### Claim 13 (depends on 12)

The method of claim 12, wherein the immunosuppressant is delivered 100 cm or less from the one or more sites of disease.

### Claim 14 (depends on 1)

The method of claim 1, wherein the immunosuppressant is delivered at the cecum, the ascending colon, or the distal portion of the ileum.

### Claim 15 (depends on 1)

The method of claim 1, wherein the disease of the GI tract is an inflammatory bowel disease.

### Claim 16 (depends on 1)

The method of claim 1, wherein the immunosuppressant is a calcineurin inhibitor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the immunosuppressant is selected from cyclosporine A, tacrolimus, or generic equivalents thereof.

### Claim 18 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a solution.

### Claim 19 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is a suspension.

### Claim 20 (depends on 1)

The method of claim 1, wherein delivery of the therapeutically effective amount of the Immunosuppressant at the desired location in the GI tract does not comprise releasing more than 10% of the immunosuppressant at a location that is not proximate to a site of disease.
